By Jonathan Stempel

NEW YORK, Dec 2 (Reuters) – CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid and other government healthcare programs, U.S. Attorney Jay Clayton in Manhattan said on Tuesday.

The settlement resolves charges that CVS violated the federal False Claims Act between January 1, 2010 and December 31, 2020 by dispensing more insulin pens than doctors prescribed, obtaining reimbursements for premature refills, and underreporting how much insulin its pharmacies dispensed.

CVS allegedly instructed pharmacy staff to report the maximum days-of-supply allowed when dispensing full insulin pen cartons, to ensure it could fill prescriptions as quickly as possible

See Full Page